Olivia M Dong
Overview
Explore the profile of Olivia M Dong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel J, Chaihorsky L, Dong O, Lu C, Moretz C, Reese E, et al.
Am J Manag Care
. 2025 Feb;
31(2):e47-e55.
PMID: 39977287
Objectives: To evaluate medical policy determinations for pharmacogenetic (PGx) testing for 65 clinically relevant drug-gene pairs and evidence cited to support determinations across major US health plans and laboratory benefit...
2.
Herring W, Gallagher M, Shah N, Morse K, Mladsi D, Dong O, et al.
Pharmacoeconomics
. 2024 Apr;
42(6):693-714.
PMID: 38684631
Background And Objective: Gene therapies for sickle cell disease (SCD) may offer meaningful benefits for patients and society. This study evaluated the cost-effectiveness of lovotibeglogene autotemcel (lovo-cel), a one-time gene...
3.
Dong O, Friede K, Chanfreau-Coffinier C, Voora D
Eur Heart J Qual Care Clin Outcomes
. 2022 Jun;
9(3):249-257.
PMID: 35652783
Aims: CYP2C19-guided P2Y12 inhibitor selection can reduce cardiovascular (CV) events and bleeding in patients with acute coronary syndromes (ACSs) post-percutaneous coronary intervention (PCI). The 12-month cost-effectiveness of CYP2C19-guided P2Y12 inhibitor...
4.
Perugini M, Johnson T, Beume T, Dong O, Guerino J, Hu H, et al.
Value Health
. 2022 May;
25(5):677-684.
PMID: 35500942
Objectives: Healthcare policy makers should ensure optimal patient access to medical nutrition (MN) as part of the management of nutrition-related disorders and conditions. Questions remain whether current healthcare policies reflect...
5.
Dong O, Poonnen P, Winski D, Reed S, Vashistha V, Bates J, et al.
Value Health
. 2022 Apr;
25(4):582-594.
PMID: 35365302
Objectives: A cost-effectiveness analysis comparing comprehensive genomic profiling (CGP) of 10 oncogenes, targeted gene panel testing (TGPT) of 4 oncogenes, and no tumor profiling over the lifetime for patients with...
6.
Brunette C, Dong O, Vassy J, Danowski M, Alexander N, Antwi A, et al.
J Pers Med
. 2021 Nov;
11(11).
PMID: 34834475
There is a well-validated association between (rs4149056) and statin-associated muscle symptoms (SAMS). Preemptive pharmacogenetic (PGx) testing may diminish the incidence of SAMS by identifying individuals with increased genetic risk before...
7.
Dong O, Roberts M, Wu R, Voils C, Sperber N, Gavin K, et al.
Pharmacogenomics
. 2021 Oct;
22(17):1121-1133.
PMID: 34704830
The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Surveys evaluating implementation resources and processes were distributed to implementation teams, providers,...
8.
Sperber N, Dong O, Roberts M, Dexter P, Elsey A, Ginsburg G, et al.
J Pers Med
. 2021 Aug;
11(7).
PMID: 34357114
The complexity of genomic medicine can be streamlined by implementing some form of clinical decision support (CDS) to guide clinicians in how to use and interpret personalized data; however, it...
9.
10.
Dong O, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley M, Meyer L, et al.
Pharmacogenomics
. 2021 Jan;
22(3):137-144.
PMID: 33403869
In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to...